Methods for inducing protective immunity against human immunodeficiency virus infection
Compositions, vaccines and methods for inducing protective immunity against Human Immunodeficiency Virus (HIV) infection are described. Heterologous vaccine combinations of one or more viral expression vectors and an isolated antigenic polypeptide induced strong protective immunity against infections by one or multiple clades of HIV.
1. A method of inducing an immune response against a human immunodeficiency virus (HIV) in a subject, the method comprising:
(i) administering to the subject a primer composition comprising an immunogenically effective amount of one or more adenovirus 26 (rAd26) vectors encoding one or more HIV antigenic polypeptides comprising amino acid sequences selected from the group consisting of SEQ ID NOs: 1-4, respectively, and a pharmaceutically acceptable carrier; and
(ii) administering to the subject a first booster composition comprising an immunogenically effective amount of an isolated HIV envelope polypeptide comprising at least one of a stabilized trimer of HIV gp140 comprising the amino acid sequence of SEQ ID NO: 5 and a stabilized trimer of HIV gp140 comprising the amino acid sequence of SEQ ID NO: 6, and a pharmaceutically acceptable carrier; and
(iii) administering to the subject a second booster composition together with the first booster composition, the second booster composition comprising an immunogenically effective amount of one or more additional adenovirus 26 (rAd26) vectors encoding one or more additional HIV antigenic polypeptides comprising amino acid sequences selected from the group consisting of SEQ ID NOs: 1-4, respectively, and a pharmaceutically acceptable carrier;
wherein the first and second booster compositions are administered after the primer vaccine is administered.
2. The method of claim 1 , wherein the first and second booster compositions are present in separate compositions.
3. The method of claim 1 , wherein the immunogenically effective amount of the isolated HIV envelope polypeptide comprises a stabilized trimer of HIV gp140 having the amino acid sequence of SEQ ID NO: 5.
4. The method of claim 1 , wherein the immunogenically effective amount of the isolated HIV envelope polypeptide comprises a stabilized trimer of HIV gp140 having the amino acid sequence of SEQ ID NO: 6.
5. The method of claim 3 , wherein the immunogenically effective amount of the isolated HIV envelope polypeptide further comprises a stabilized trimer of HIV gp140 having the amino acid sequence of SEQ ID NO: 6.
6. The method of claim 1 , wherein the primer composition and the second booster composition are identical.
7. The method of claim 3 , wherein each of the one or more rAd26 vectors and the one or more additional rAd26 vectors are replication deficient.
8. The method of claim 1 , wherein the immune response is a protective immune response.
9. The method of claim 1 , wherein the first and second booster compositions are first administered at about 22-26 weeks after the primer composition is initially administered.
10. The method of claim 9 , wherein the primer composition is re-administered at about 10-14 weeks after the primer composition is initially administered.
11. The method of claim 1 , wherein the subject is a human.
12. The method of claim 1 , wherein administration of the primer composition and first and second booster compositions induces an immune response against multiple clades of HIV.
13. The method of claim 1 , wherein the first booster composition further comprises aluminum phosphate.
14. The method of claim 1 , wherein the one or more rAd26 vectors in the primer composition and second booster composition encode HIV antigenic polypeptides having the amino acid sequences of SEQ ID NOs: 1, 3, and 4, respectively.
15. A method of inducing an immune response against a human immunodeficiency virus (HIV) in a subject, the method comprising:
(i) administering to the subject a primer composition comprising an immunogenically effective amount of one or more adenovirus 26 (rAd26) vectors encoding HIV antigenic polypeptides having the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 4, respectively, and a pharmaceutically acceptable carrier; and
(ii) administering to the subject a first booster composition comprising an immunogenically effective amount of an isolated HIV envelope polypeptide comprising a stabilized trimer of HIV gp140 having the amino acid sequence of SEQ ID NO: 5, and a pharmaceutically acceptable carrier; and
(iii) administering to the subject a second booster composition together with the first booster composition, the second booster composition comprising an immunogenically effective amount of one or more additional rAd26 vectors encoding HIV antigenic polypeptides having the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 4, respectively, and a pharmaceutically acceptable carrier;
wherein the first and second booster compositions are administered after the primer vaccine is administered.
16. The method of claim 15 , wherein the one or more rAd26 vectors consist of three rAd26 vectors of which a first rAd26 vector encodes an HIV antigenic polypeptide comprising the amino acid sequence of SEQ ID NO: 1, a second rAd26 vector encodes an HIV antigenic polypeptide comprising the amino acid sequence of SEQ ID NO: 3, and a third rAd26 vector encodes an HIV antigenic polypeptide comprising the amino acid sequence of SEQ ID NO: 4, and the one or more additional rAd26 vectors also consist of the three rAd26 vectors.
17. The method of claim 15 , wherein each of the rAd26 vectors is replication deficient.
18. The method of claim 15 , wherein the first and second booster compositions are first administered at about 22-26 weeks after the primer composition is initially administered.
19. The method of claim 15 , wherein the primer composition is re-administered at about 10-14 weeks after the primer composition is initially administered.
20. The method of claim 19 , wherein the first and second booster compositions are re-administered to the subject.
21. The method of claim 15 , wherein administration of the primer composition and first and second booster compositions induces an immune response against multiple clades of HIV.
22. The method of claim 15 , wherein the immune response is a protective immune response.
23. The method of claim 15 , wherein the primer composition and first and second booster compositions are administered by intramuscular injection.
24. The method of claim 15 , wherein the subject is a human.
25. The method of claim 15 , wherein the first booster composition further comprises aluminum phosphate.
26. The method of claim 15 , wherein the first and second booster compositions are present in separate compositions.
27. The method of claim 1 , wherein the one or more rAd26 vectors in the primer composition and second booster composition encode HIV antigenic polypeptides having the amino acid sequences of SEQ ID NOs: 1, 3, and 4, respectively; and the immunogenically effective amount of the isolated HIV envelope polypeptide comprises a stabilized trimer of HIV gp140 having the amino acid sequence of SEQ ID NO: 5 and a stabilized trimer of HIV gp140 having the amino acid sequence of SEQ ID NO: 6.